Director Share Purchase

RNS Number : 7377P
ReNeuron Group plc
21 October 2021
 

ReNeuron Group plc

("ReNeuron" or the "Company")

 

Share Purchase by a Director

 

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, was informed that on the 20 October 2021, the following purchase of the Company's ordinary shares of 1p each ("Ordinary Shares") was made by a director of the Company:

 

Name

Title

Number of Ordinary Shares purchased

Total beneficial interest in the Company's Ordinary Shares

Percentage of Company's Total Voting Rights

Barbara Staehelin

Senior Independent

Non-Executive Director

43,000

43,000

0.08%

 

  ENDS

 

Contacts:

 

ReNeuron

www.reneuron.com/investors

Olav Hellebø, Chief Executive Officer

Catherine Isted, Chief Financial Officer

Via Walbrook PR

 

 

Stifel Nicolaus Europe Limited (NOMAD and Joint Broker)

Ben Maddison, Stewart Wallace

+44 (0)20 7710 7600

 

 

 

Allenby Capital Limited (Joint Broker)

+44 (0)20 3328 5656

James Reeve/George Payne (Corporate Finance)

 

Stefano Aquilino (Sales & Corporate Broking)

 

 

 

Walbrook PR (Media & Investor Relations)

+44 (0)20 7933 8780 or reneuron@walbrookpr.com

Paul McManus / Alice Woodings

+44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

 

About ReNeuron

 

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead cell therapy candidate is in clinical development for the blindness-causing disease, retinitis pigmentosa.

 

ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the brain. The Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make any tissue cells of choice; in-house programmes are focused on treatments for blood cancers and diabetes.

 

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  For further information visit www.reneuron.com

 

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

 (Disclosure in relation to share options granted to Directors and PDMRs)

 

 

 1 

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Barbara Staehelin

2

Reason for the notification 

a)

Position/status 

Senior Independent Non-Executive Director

b)

Initial notification /Amendment 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name 

ReNeuron Group plc

b)

LEI 

2138003TU12CQ5TZO137

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument 

Identification code 

Ordinary Shares 1p

RENE - GB00BF5G6K95

b)

Nature of the transaction 

Acquisition of ordinary shares

c)

Price(s) and volume(s)

 

 Price(s) 

Volume(s)

115p

43,000

 

d)

 

Aggregated information 

£49,450

e)

Date of the transaction 

20 October 2021

f)

Place of the transaction 

London Stock Exchange AIM Market

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHURVWRAAURUAA
UK 100

Latest directors dealings